Bone grafts and biomaterials substitutes for bone defect repair: A review

Wenhao Wang a, b, Kelvin W.K. Yeung a, b,*

a Department of Orthopaedics and Traumatology, The University of Hong Kong, Pokfulam, Hong Kong, China
b Shenzhen Key Laboratory for Innovative Technology in Orthopaedic Trauma, The University of Hong Kong Shenzhen Hospital, 1 Haiyuan 1st Road, Futian District, Shenzhen, China

ABSTRACT

Bone grafts have been predominated used to treat bone defects, delayed union or non-union, and spinal fusion in orthopaedic clinically for a period of time, despite the emergence of synthetic bone graft substitutes. Nevertheless, the integration of allogeneic grafts and synthetic substitutes with host bone was found jeopardized in long-term follow-up studies. Hence, the enhancement of osteointegration of these grafts and substitutes with host bone is considerably important. To address this problem, addition of various growth factors, such as bone morphogenetic proteins (BMPs), parathyroid hormone (PTH) and platelet rich plasma (PRP), into structural allografts and synthetic substitutes have been considered. Although clinical applications of these factors have exhibited good bone formation, their further application was limited due to high cost and potential adverse side effects. Alternatively, bioinorganic ions such as magnesium, strontium and zinc are considered as alternative of osteogenic biological factors. Hence, this paper aims to review the currently available bone grafts and bone substitutes as well as the biological and bio-inorganic factors for the treatments of bone defect.

1. Introductions

Bone grafting is one of the most commonly used surgical methods to augment bone regeneration in orthopaedic procedures [3]. Over two million bone grafting procedures were performed annually worldwide, which is the second most frequent tissue transplantation right after blood transfusion [4]. Among all clinical available grafts, autologous bone is still being considered as the gold standard since all necessary properties required in bone regeneration in term of osteoconduction, osteoinduction and osteogenesis are combined [5]. However, the concerns of limited supply and donor site complications are still maintained. Bone allografts dominantly share the second higher option for orthopaedic surgeons and nearly one third of all bone grafts used in North America are allografts [6] since they are available in various forms and large quantities. They are primarily osteoconductive, while reduced osteoinductivity is retained only in demineralized bone matrix (DBM) preparations [7]. Nevertheless, inferior healing was observed compared to the use of autologous grafts and potential for transmission of disease and other infective agents were also reported [8,9]. More importantly, the amounts of available natural bone grafts traditionally used are still far from meeting the clinical demands, especially when facing the impending global pandemic of aging and obesity [10].

To address these limitations, tremendous alternatives and options have been brought by the emergence of synthetic bone substitutes during the past decades, which made bone grafts and substitutes (BGS) among the most promising market in the orthopaedic industry and it is reported that the revenue from the global market is over two billions in 2013 [11]. Bone grafting procedures are also being gradually shifted from natural grafts to synthetic bone substitutes and biological factors [11]. Among those synthetic bone substitutes and biological factors, calcium phosphate (CaP)-based biomaterials (e.g. hydroxyapatite (HAp), CaP cements and ceramics), and recombinant human bone morphological proteins (rhBMPs, e.g. rhBMP-2 and rhBMP-7) are most widely used, either alone or combined [12]. The former bone substitutes are generally reduced osteoinductivity is retained only in demineralized bone matrix (DBM) preparations [7]. Nevertheless, inferior healing was observed compared to the use of autologous grafts and potential for transmission of disease and other infective agents were also reported [8,9]. More importantly, the amounts of available natural bone grafts traditionally used are still far from meeting the clinical demands, especially when facing the impending global pandemic of aging and obesity [10].

To address these limitations, tremendous alternatives and options have been brought by the emergence of synthetic bone substitutes during the past decades, which made bone grafts and substitutes (BGS) among the most promising market in the orthopaedic industry and it is reported that the revenue from the global market is over two billions in 2013 [11]. Bone grafting procedures are also being gradually shifted from natural grafts to synthetic bone substitutes and biological factors [11]. Among those synthetic bone substitutes and biological factors, calcium phosphate (CaP)-based biomaterials (e.g. hydroxyapatite (HAp), CaP cements and ceramics), and recombinant human bone morphological proteins (rhBMPs, e.g. rhBMP-2 and rhBMP-7) are most widely used, either alone or combined [12].
only osteoconductive and mainly being applied in reconstruction of large bone defects, while the rhBMPs are basically osteoinductive with the capability of enhancing the fracture healing [3]. However, the clinical applications of BMPs as off-label drug have been concerned due to supraphysiologic dosage, adverse clinical outcomes and cost issue [11,13,14]. The applications of stem cell therapy and natural bioinorganic ions as well as the musculoskeletal tissue engineering approach have been extensively investigated [15–19].

2. Biological structure of bone and its regeneration

2.1. The biology of bone structure

As a rigid organ in body, the bone is able to support and protect various organs but is also able to facilitate mobility [20]. These properties are mainly attributed to the remarkable hierarchical architecture, which is constituted by the soft collagen protein and stiffer apatite mineral, as shown in Fig. 1 [21]. Although the bone structures of different types and species are diverse at the macroscopic level, and the organizations of collagen and minerals are not completely understood, the mineralized fibrils, which is assembled by collagen molecules and mineralized by apatite crystals during the formation of the bone, still acts as the bone’s universal elementary building block [22–24]. In the body, the functionality of bone tissue is related to stiffness, which is directly determined by the natural mineral content within the collagen/mineral composite. For instance, over 80% of mineral content makes the ear vibratable for the purpose of transmitting sound with high fidelity, but it is unable to resorb energy [20]. In contrast, less dense mineral content can enable deer antlers to deform while absorbing energy, but they are non-load bearing [25]. Specific to the long bone, the constitution of mineral content is over 20% [26], which endows the bone to absorb the energy and keeps it light to allow mobility.

The bone, once formed, is maintained dynamically through two different processes, modeling and remodeling [27], which are also employed in bone fracture recovery. In bone modeling process, the new bone is formed without prior bone resorption, while in the bone remodeling process, bone formation follows bone resorption [20]. Bone modeling is vigorous during growth, altering the shape and size of the bone. It continues in adulthood, by increasing the ability to resist bending and adapt to functional challenges [28,29]. On the other hand, bone remodeling is a lifelong process that begins in early fetal life [30], and is in charge of maintaining bone function by continuously replacing damaged bone with new bone [28]. It is reported that about 25% of trabecular bone and 3% of cortical bone are removed and replaced every year [31].

2.2. The biology of bone regeneration

The dynamic equilibrium of the bone efficiently prevents the bone fracture, except for the emergence of a load exceeding the bone strength, or the gradually accumulated damage under cyclic loading (well below bone strength) [32,33]. Unlike other tissues, bone healing is found to be the recapitulation of the ontological events that take place during embryonic development of the skeleton, which enables the damaged organ to by fully restored to its pre-injury composition, structure and function [34]. Various factors affecting repairing can be applied to classify bone healing, and the extent of tissue loss is among them [35]. Consequently, bone repair can be defined into two categories: primary bone healing and secondary bone healing.

Primary (direct) bone healing mainly happens when the fracture gap is less than 0.1 mm and the fracture site is rigidly stabilized. It is proposed that the bone gap in this process is filled directly by continuous ossification and subsequent Haversian remodeling [36], with the absence of cartilaginous or connective tissue. The formation of callus is also suppressed [35,37]. However, it must be noted that the concept of direct continuous bone formation is controversial due to the lack of neither histological evidence [35] and clinical cases [38].

Secondary (indirect) bone healing is the more common form of bone healing and occurs when the fracture edges are less than twice the diameter of the injured bone [35]. In general, multi events, such as blood clotting, inflammatory response, fibrocartilage callus formation, intramembranous and endochondral ossification, and bone remodeling are involved in the secondary bone fracture repair. Specific to the major metabolic activity, anabolism in a bone fracture is activated initially in the form of increasing bone volume by recruiting stem cells differentiation and retardation with chondrocyte apoptosis [39,40]. The anabolic activity continues in a prolonged phase, which is dominated by catabolic activities. The reduction of callus tissue volume is the symbol of this activity. When the vascular bed increases and vascular flow rate returns to pre-injury level, the catabolic phase reaches the final period [41,42]. The biological events and activities, as well as the cells involved in typical bone fracture healing at different phases are illustrated in Fig. 2 [34].

The large segmental bone defect, or alternatively as critical-sized defect, is an extreme condition in bone healing, which can be caused by high energy trauma, diseases, developmental deformities, revision surgery and tumor resection or osteomyelitis [43–46]. The extensive bone loss in this defect has been shown to directly affect revascularization and tissue differentiation, and eventually leads to spontaneous bone fracture, which progresses to non-union without interventions [35,47]. The classical definition of

---

**Fig. 1.** The hierarchical structure of bone ranging from microscale skeleton to nanoscale collagen and hydroxyapatite. Reprinted by permission from Macmillan Publishers Ltd: Nature Communication [21], copyright (2013).
a critically sized segmental bone defect is ‘the smallest osseous defect in a particular bone and species of animal that will not heal spontaneously during the lifetime of the animal’ [48, 49] or ‘shows less than 10% bony regeneration during the lifetime of the animal’ [49, 50]. Even defect size is not the sole parameter to characterize a bone defect as critical [51], it has been found that in most species a length exceeding 2−2.5 times the diameter of the affected bone can be considered the minimum size [35, 52, 53]. The non-union caused by such defects can highly influence the quality of patients’ lives due to the prolonged and postoperative treatment costs and also pose a major surgical, socio-economical and research challenges [43].

3. Bone grafts and substitutes for bone defect treatments

Bone substitutes mainly serve as combined functions of mechanical support and osteo-regeneration [54], which involve three important biological properties: osteoconduction, osteoinduction and osteogenesis [55]. Osteoconduction refers to the ability to support the attachment of osteoblast and osteo-progenitor cells, and allow the migration and ingrowth of these cells within the three-dimensional architecture of the graft [55]. Osteoinduction describes that the graft can induce the primitive, undifferentiated and pluripotent cells to develop into the bone-forming cell lineage, by which osteogenesis is induced [55, 56]. Osteogenesis means the osteo-differentiation and subsequently new bone formation by donor cells derived from either the host or grafts [5, 57]. Besides, osteointegration, which defines as the ability of an implant anchoring with the formation of bony tissue around the implant at the bone-implant interface without the formation of fibrous tissue [55], is also an important criterion in evaluating the result of bone healing. The biological properties of some commonly used bone grafts and substitutes are listed in Table 1.

3.1. Natural bone grafts

3.1.1. Autologous bone grafts

An osseous graft harvested from an anatomic site and transplanted to another site within the same individuals is called autologous bone grafting [57, 58]. With the possession of osteo-conductive, osteoinductive and osteogenic properties, an autologous bone graft can integrate into the host bone more rapidly and completely [58], therefore being regarded as the gold standard in treating bone defects and the benchmark in evaluating other bone grafts and substitutes. However, the drawbacks of the autograft have been extensively reported, and are related to the harvesting process, including donor site complication and pain, increased blood loss, increased operative time, potential for donor site infection and limited volume of material available [54, 57, 59, 60].

The development of reamer-irrigator-aspirator (RIA) system offers an alternative to other traditional autologous bone graft options such as iliac crest bone graft, with which the graft can be harvested from intramedullary canal of the femur or tibia [61]. In a systematic review covering over 6000 patients, the complication
rate with the usage of RIA device is found reduced to 6% as compared to 19.37% from iliac crest bone [62]; while the bone volume is increased from the mean of 15–20 ml with traditional iliac crest bone harvesting to over 40 ml by using RIA [63,64]. By comparing the bone grafts harvested from different parts of the same patient, higher levels of expression of genes associated with vascular, skeletal and hematopoietic tissues were identified in the RIA samples as compared to that from the iliac crest bone, while stem cells and growth factors in the RIA samples were also more abundant [65]. Nevertheless, the corresponding complications of RIA were also documented, which mainly include iatrogenic fracture, anterior cortical perforation, exsanguination, and heterotopic ossification [62,66].

Cancellous autografts are the most commonly used form of autologous bone grafting. Few osteoblasts and osteocytes, but abundant mesenchymal stem cells (MSCs) survive as a result of ischemia during transplantation, which helps maintain osteogenic potential and the ability to generate new bone from the graft [1,67]. Additionally, the large surface area of a cancellous autograft facilitates the superior revascularization and incorporation of the graft locally to the host bone [54]. The graft-derived proteins, which are attributed to the osteoinduction of the graft, are also preserved and present when the autografts are appropriately treated [54,58]. In the early phase of autograft transplantation, hematoma and inflammation are formed rapidly with the recruitment of MSCs to lay down fibrous granulation tissue. Meanwhile, the necrotic graft tissue is slowly eliminated by macrophages and neovascularization also happens. Next, during the incorporation of the autograft, seams of osteoid are produced [54,57,58]. This current with the formation of new bone by accumulated hematopoietic cells within the transplanted bone [54,57,58]. This process, which leads to the complete resorption and replacement of the graft, usually takes 6–12 months [68].

Cortical autografts possess excellent structural integrity and are mechanical supportive, due to their limited number of osteoprogenitor cells [57]. Unlike the autologous cancellous graft, the creeping substitution of cortical autograft is mainly mediated by osteoclasts after the rapid hematoma formation and inflammatory response in the early phase of bone regeneration, since the revascularization and remodeling processes are strictly hampered by the dense architecture [58]. Consequently, the appositional bone growth over a necrotic core is the dominant means incorporation of the cortical autograft following osteoclast resorption [69,70]. This process may take years, depending on the graft size and implantation site [54,58].

### 3.1.2. Allogeneic bone grafts

Allogeneic bone graft refers to bony tissue that is harvested from one individual and transplanted to a genetically different individual of the same species [57,58]. Considering the limitation of autologous bone grafts, bone allograft is considered the best alternative to autografts and has been used effectively in clinical practice in many circumstances, especially for those patients with poor healing potential, established nonunion, and extensive comminution after fractures [1,58]. The allograft may be machined and customized, and is therefore available in a variety of forms, including cortical, cancellous and highly processed bone derivatives (i.e., demineralized bone matrix) [57]. Compared to autografts, allografts are found to be immunogenic and demonstrate a higher failure rate, which is believed to be caused by activation major histocompatibility complex (MHC) antigens [9]. The initial osteoinduction phase would be destroyed by immune response and inflammatory cells, which could quickly surround the neo-vascular, causing the necrosis of osteo-progenitor cells
[71–73]. Even the exact mechanism of immune response in bone allograft incorporation is not clear; studies have found that allograft acceptance is improved when the immunogenicity is reduced by modifying the allograft to narrow histocompatibility differences [58]. Another issue is the risk of viral transmission, which has been significantly improved by the development of modern tissue banks [54] and improvement in processing technology [74]. Based on these situations, the application of fresh allografts is always limited, and preserved modified allografts are usually preferred in clinical practices [75].

Cancellous allografts are the most common types of commercial allogeneic grafts and are supplied predominately in the form of cuboid blocks [57]. Due to the litter mechanical property they confer and their relative poor healing promoting ability, preserved modified cancellous allografts are mainly applied in scenarios such as spinal fusion augmentation and filler material for cavitory skeletal defects [54,58]. Compared to autografts, a similar but slower sequence of events happens in the incorporation process of allografts [58]. However, osteointegration may be delayed by a host inflammatory response which leads to the formation of fibrous tissue around the graft, this was found in less than 10% of cases [76]. Meanwhile, the allografts remain entrapped and are never completely resorbed many years after transplantation [58]. The incorporation of a cortical allograft is also preceded by creeping substitution, which is similar to its autogenous counterpart. In general, the process is initiated by the osteoclastic resorption and followed by sporadic formation of new appositional bone through osteoconduction [1,58].

Demineralized bone matrix (DBM) is a kind of highly processed allograft derivative with at least 40% of the mineral content of the bone matrix removed by mild acid, while collagens, non-collagenous proteins and growth factors remain [77]. Inferior structural integrity and mechanical properties impart that the DBM is mainly applied for filling large skeletal defects where immediate loading-bearing resistance is required [57]. In consideration of immune responses and for safety, frozen or freeze-dried products that are free of marrow and blood are commonly transplanted [58]. The incorporation of a cortical allograft is also preceded by creeping substitution, which is similar to its autogenous counterpart. In general, the process is initiated by the osteoclastic resorption and followed by sporadic formation of new appositional bone through osteoconduction [1,58].

3.2. Synthetic bone graft substitutes

As mentioned in the previous paragraphs, the serious shortage of natural bone grafts and the little chance of supply meeting the demands in an aging population [79] has triggered the blossom of bone grafts and substitutes (BGS) market [80]. Calcium sulfate, calcium phosphate (CaP) ceramics, CaP cements, bioactive glass or combinations thereof are most commonly synthetic bone substitutes available at present [81].

3.2.1. Calcium sulfate

Calcium sulfate, also known as plaster of Paris, is a kind of osteoconductive and biodegradable ceramics composed of CaSO4 and has been applied in filling void defects since 1892 [82]. It is prepared by heating gypsum with a patented alphahemihydrate crystal structure and can be made in different forms, such as hard pellets or injectable viscous fluids that harden in vivo [57]. Although lacking a macroporous structure, calcium sulfate still has a rapid resorption rate and weak internal strength, which implies that it can only be used to fill small bone defects with rigid internal fixation, the ingrowth of vascular and new bone happens in conjunction with the resorption of the graft [83]. Niu et al. [84] have reported that calcium sulfate was unable to achieve an optimal fusion rate in spinal arthrodesis, mainly because of faster degradation in early phase of bone regeneration than actual bone deposition. However, easy preparation and relative low cost has made calcium sulfate resurgent when combined with other synthetic bone substitutes and/or growth factors [79].

One of the promising approaches is to load antibiotics to this biomaterial. From June 2015 to November 2015, M. Glombitza and E. Steinhausen [85] were using a vancomycin-loaded calcium sulfate/hydroxyapatite to treat the chronic osteomyelitis caused by multi-resistant bacterial for 7 patients, and rapid control of infection was achieved in 6 patients. However, as what can be expected, the replacement of the composite by new bone was not uniform. More recently, Nan Jing et al. [86] modified the traditional Masquelet technique, which has been widely used in treating massive bone defects, by using calcium sulfate to replace the PMMA as cement spacer, so as to make this technique a one-step surgery. In this case report regarding the reconstruction of an open fracture of the calcaneus at right foot, they found the formation of the induced membrane with the implantation of calcium sulfate by X-ray image and a computed tomography scan. But this trial was then stopped by the patient and the calcium sulfate was finally replaced by autologous iliac crest bone grafts, and further characterization on the induced membrane and bone regeneration became impossible [86].

3.2.2. Calcium phosphate ceramics (CaP ceramics)

Calcium phosphate ceramics are constituted by calcium hydroxyapatites, which is a chemical composition similar to the mineral phase of calcified tissues [87]. They are synthetic mineral salts and usually produced by sintering at high temperatures with the exclusion of water vapor and subsequently molded by high-pressure compaction [83]. Porous implants, non-porous dense implants and granular particles with pores are common commercially available forms. As a kind of bioabsorbable ceramic with excellent osteoconductivity, CaP ceramics have received great attention and have been experimented extensively in clinical studies [88–92]. Unlike the calcium-to-phosphate (Ca/P) ratio of biphasic calcium phosphate (BCP), the ratio of HAP and tricalcium phosphate (TCP), which are most widely used in orthopaedics, can be identified. Several key parameters of CaP ceramics, such as absorption rate and mechanical properties, are strictly related to the Ca/P ratios. In addition, the crystal and porous structure is a highly-considered factor in choosing CaP ceramics.

Hydroxyapatites (HAp) is a natural occurring mineral form of calcium apatite with the formula of Ca10[PO4]6[OH]2 and comprises about 50% of the weight of the bone, which accounts for its excellent osteoconductive and osteointegrative properties [1,57]. Meanwhile, HAp has a similar initial mechanical property compared to the cancellous bone—brittle and weak under tension and shear but resistant to compressive loads [87] and may decrease by 30–40% in situ after being implanted for several months [93]. The macroporosity (pore with diameters > 100 μm) and pore interconnectivity of synthetic HAp allow the adhesion, proliferation, and differentiation of osteoprogenitor cells, as well as the revascularization, and subsequently ingrowth of new bone, when implanted in vivo [94,95]. However, the relatively high Ca/P ratio and crystallinity delay the resorption rate of HAp—a process
predetermined by giant cells and macrophages [96]. It has been demonstrated that when porous hydroxyapatite cylinders were implanted in the cancellous bone of rabbits, only 5.4% volume reduction was observed after six months, whereas the number for tricalcium phosphate ceramic was 85.4% under the same conditions [94]. Consequently, the remaining hydroxyapatite grafts within the host bone would compromise the intrinsic strength of the bone at the callus site due to the decreasing of mechanical properties aforementioned [83]. Therefore, HAp alone is more often applied as a coating on implants and external fixator pins or in sites with low mechanical stress [197].

These drawbacks may partially being overcome by the recent development of nanocrystalline HAp, with which larger surface to volume ratio is conferred. This great surface not only significantly reduced the sintering temperature of HAp ceramic, but also led to the increased resorption rate [98]. However, this increasing is not noticeable in clinical observation [99]. On the other hand, efforts were also being made to enhance the mechanical performance of nano-HAp by incorporation of carbon nanotubes (CNTs) [98,100,101]. The addition of CNTs, on one hand, increased the open porosity from about 2.52% (pure nano-HAp) to at most 7.93% (with addition of 2 wt.% of CNTs), on the other hand, fracture toughness with the value of 1.88 MPa m^{1/2} which is similar to that of the human cancellous bone, was achieved when the addition amount was 1% weigh percentage [101]. Enhanced bone formation was also observed in rabbit distal femur bone defect model, whereas toxicity was not exhibited in the liver and kidney. Nevertheless, the resorption rate of this nanocomposite was not fully investigated and the enhanced mechanical properties are insufficient to extend the application of HAp in clinic.

**Tricalcium phosphate (TCP),** especially the rhombohedral β-form, β-tricalcium phosphate (β-TCP), has attracted increased attention since it was first reported in 1920 by Albee [102]. With the chemical formula of Ca_{3}(PO_{4})_{2}, β-TCP has Ca/P ratio of 1.5 and is thus lower than that of hydroxyapatite that may partially accelerate its degradation and absorption [67]. Like HAp, TCP has even more interconnected porous structures that can directly benefit fibrovascular invasion and bony replacement [1], but at the same time weaken mechanical properties [103]. Due to the thermodynamically unstable physiological pH, a portion of TCP would inevitably convert into hydroxyapatite after implantation and thus partially hamper the degradation of TCP [104], the majority would be resorbed by phagocytosis after 6–24 months with some remaining for years [105]. This makes the TCP effective for filling bone defects caused by trauma and benign tumors but is not favored as a bone-graft substitute owning to an unpredictable biodegradation profile [78].

Recent research started to focus on the enhanced angiogenesis in which the tricalcium phosphate was applying to augment of bone defects [106,107]. By comparing the in vitro neo-vascularization capacity of four different types of CaP ceramics, namely HAp, BCP-1 (HAp: β-TCP = 70/30), BCP-2 (HAp: β-TCP = 30/70) and β-TCP, they found human umbilical vein endothelial cells (HUVECs) demonstrated significantly up-regulated proliferation and angiogenesis when cultured with β-TCP and BCP-2, which containing higher amount of β-TCP phase [106]. While in the mice intramuscular implantation model, CaP ceramics containing higher content of β-TCP also induced higher density of microvessels [106]. Variety of hypotheses, such as the porous structure [108–110], effects of ionic transfer upon degradation of CaP ceramics and homeostasis [111–113], potential strains imposed on CaP during degradation [114,115], were proposed to explain the mechanism, nevertheless, crucial investigation is still missing and further studies are necessarily important.

**Biphasic calcium phosphate (BCP)** is another widely used commercial ceramic obtained by mixing hydroxyapatite and tricalcium phosphate in different concentrations for the purpose of combining the advantages of both calcium salts [116]. By adjusting the formulation, the dissolution rate and mechanical properties can be controlled within ranges and subsequently applied in bulk or as implant coatings [117].

### 3.2.3. Calcium phosphate cements (CPC)

Calcium phosphate cements, unlike CaP ceramics, usually involve two compounds, one of which is an aqueous curing agent. They were invented by Brown and Chow [118,119] for the purpose of extending the adaptability and moldability of CaP bone substitutes in the 1980s. They were approved by US Food and Drug Administration (FDA) [87] in 1996. They can be conveniently injected to fill defects with various shapes and subsequently solidified by mixing with an aqueous phase through isothermic reaction. Self-hardened CPCs are generally highly microporous, biocompatibility and mechanical supporter with low bending strength [120]. However, they can only degrade layer by layer as predetermined by the dissolution in physiological conditions and osteoclast resorption activity; subsequently, an ingrowth of neo-vascular and bone tissue is theoretically hampered compared to the other CaP ceramics that support interconnected macroporosity [87]. According to the optimization of CPCs and brushite CPCs, several types can be identified; properties of CPCs in terms of feasibility, setting reaction and biodegradation rates are highly related to its composition. Apatic CPCs are viscous, indicating relatively poor injectability, but a setting reaction can occur at the physiological pH value and the mechanical properties are slightly stronger than brushite CPCs. Due to the low crystalline structure of the obtained calcium deficient-hydroxyapatite after hardening, a higher degradation rate was demonstrated but still incomplete [121]. The brushite CPCs are feasible for injection and solidify quickly at a low pH value (<6) [120]. They demonstrate higher degradability, but unpredictable degradation was reported due to the kinetic favorable transformation to hydroxyapatite [104]. Based on its flow behavior before setting, CPCs are clinically favored for bone replacement, especially in percutaneous vertebroplasty [122–124] and kyphoplasty [125,126], but not as bone substitutes.

Similar to the CaP ceramics, in order to promote the mechanical properties and biological performances of CPCs, the preparation of nanostructured CaP is developed. Even the up-regulated cell attachment and proliferation, as well as the in vivo bone regeneration was achieved in several investigations [127–129], the motivation of applying nanostructured CPCs is mainly attributed to the fact that nanosized architecture of native bone tissue and process of bone formation [130–133], whereas the cellular and molecular mechanism has not been fully elaborated [128]. The incorporation of fibers, which is also inspired by the hierarchical nanostructured of bone, is another approach that being widely investigated to enhance the mechanical strength of CPCs [134]. However, the evidence that these modifications benefit the clinical practice is still missing [135].

Phase separation, which means the separation of powder and liquid components during injection, is another important concern associated with the clinical applications of CPCs [136]. By extracting other crucial properties of CPCs, several methods have achieved clinical success in some applications after the abundant studies over the past two decades [137–141]. However, recent research tended to gain the relationship of those critical parameters of CPCs by theoretical calculations and analysis [142–148], due to the extremely difficult optimization by sole experimental work. Since these studies can still hardly being reflected in real experimental practice and thus affect the clinical applications of the CPCs, they will not be highlighted in this review but can be found in other recent review [149].
3.2.4. Bioactive glass

Bioactive glass, also known as bioglass, refers to a group of synthetic silicate-based ceramics and was originally constituted by silicon dioxide (SiO2), sodium oxide (Na2O), calcium oxide (CaO), and phosphorus pentoxide (P2O5) when first developed in 1970s [150]. This was later modified to a more stable composition by addition potassium oxide (K2O), magnesium oxide (MgO) and boric oxide (B2O3); the key component, silicate, constitutes 45–52% of its weight [11]. The optimized constitutions lead to a strong physical bonding between bioglass and host bone. This phenomenon, namely bioactivity, was first found on BGS [151]. This bone-binding property is believed to be caused by leaching and the accumulation of silicon ions when exposed to body fluids upon implantation, and the subsequent formation of hydroxyapatite coating on the surface of bioglass [152]. This thin hydroxyapatite coating absorbs proteins and attracts osteo-progenitor cells. In addition, this biological apatite layer is partially replaced by bone through a creep substitution process in long-term implantation [153]. The porosity and relative fast resorption rate in the first two weeks of implantation allows an ingrowth of neo-vascular following deposition of the new bone [12,67]. One study has demonstrated that bioglass fiber scaffolds can be completely resorbed in six months in vivo with little inflammatory response [154]. Like the other ceramics, the mechanical properties of bioglass were reported to be brittle and weak. Therefore, it has been mainly applied in the reconstruction of facial defects [155,156] when combined with growth factors [157].

Bioglass 45S5 (46.1 mol.% SiO2, 24.4 mol.% Na2O, 26.9 mol.% CaO and 2.6 mol.% P2O5, now sold by NovaBone Products LLC, US) and S53P4 (53.8 mol.% SiO2, 22.7 mol.% Na2O, 21.8 mol.% CaO and 1.7 mol.% P2O5, now sold by BonAlive Biomaterials, Finland) are two most recognized commercial available bioglasses that can be used as bone graft substitutes in the market. They are made by using the traditional melt-quenching route under high temperature (usually above 1300 °C) and thus unable to be fabricated into amorphous scaffolds due to the crystallization during sintering at that temperature. One of the exception is 13–93, with a composition of 54.6 mol.% SiO2, 6 mol.% Na2O, 22.1 mol.% CaO, 1.7 mol.% P2O5, 7.9 mol.% K2O and 7.7 mol.% MgO, does not crystallize during sintering. However, the bioactivity of 13–93 was significantly reduced in the form of prolonging the formation of hydroxyapatite layer in the stimulated body fluid (SBF) immersion tests, from 8 h on the surface of Bioglass 45S5 to 7 days on the 13–93 [159]. Several clinical trials demonstrated similarity good contact with the host bone when the S53P4 and Bioglass 45S5 was applied to treat bone defect, respectively [160–162], whereas reduced resorption of S33P4 was exhibited due to the higher silica content [156,163]. Additionally, inferior healing results were also reported when compared to autologous grafts [164,165].

The development of sol-gel processing offers another route to produce bioactive glass with porous structure ranging from mesopores to macropores [166–168], in which SBS (60 mol.% SiO2, 36 mol.% CaO and 4 mol.% P2O5) and 77S (80 mol.% SiO2, 16 mol.% CaO and 4 mol.% P2O5) are representatives. In a research involving the management of critical-sized defect at the femoral condyle of rabbits, the bone regeneration ability and in vivo degradation of melt-derived Bioglass 45S5 and sol-gel-derived bioglass 77S and SBS were compared [169]. Due to the nanoporosity and enhanced surface area, the sol-gel-derived bioglass demonstrated faster degradation speed as compared with Bioglass 45S5 between 4 and 24 weeks after implantation, whereas the bone defect filled with Bioglass 45S5 containing more bone than those filled with 77S or SBS at 8 weeks post-operation but then equalized after implantation for 12 weeks [169]. It seems the fast degradation of bioglass may lead to a higher pH value and accumulated ions in the microenvironment, which is not favored by cells, and thus jeopardized the bone ingrowth [156].

3.2.5. Poly(methyl methacrylate) (PMMA) bone cement

First employed by orthopaedic surgeons 60 years ago [170], poly(methyl methacrylate) (PMMA) remains a key component of modern practice and may be one of the most enduring materials in orthopaedic surgery [171]. It is non-biodegradable and non-resorbable, which makes it more like grout rather than cement, and thus it cannot be considered a bone substitute material even though it is the most commonly used synthetic material used in clinics [172]. Due to its high mechanical property and feasibility for handling, two-part self-polymerizing PMMA bone cement has been widely used in total joint replacement for the fixation of component [173] and percutaneous vertebroplasty [174,175]. Triggered by infection from prosthetic joints, antibiotic-loaded acrylic cement was developed and has been considered part of antimicrobial prophylaxis in primary arthroplasty [171]. However, the drawbacks of PMMA cement are clear. The polymerization of PMMA is exothermic and may potentially damage adjacent tissues [176,177]. Moreover, aseptic loosening caused by monomer-mediated bone damage [178], mechanical mismatch and inherent inert property [179], was reportedly inevitable in long-term wearing and thus led to the failure of arthroplasties using PMMA cement [180].

3.3. The adoption of growth factors on bone regeneration

Most bone graft substitutes, especially synthetic ceramics and cements, do not possess any osteoinductive property. The ability to enhance bone healing of those bone substitutes mainly relies on osteoconductive means [57]. In general, the osteoconduction of bone substitute would facilitate the migration and support attachment of progenitor cells, which would then secrete growth factors to stimulate bone formation [1]. However, in situations where the ideal environment for callus formation was disturbed, the secretion of growth factors was missing and was thereby predisposed to delayed union or even non-union [181]. Meanwhile, the requirement of osteoinductive factors presenting at the site of bone injury during bone healing is also critically important. Therefore, directly application of growth factors, some of which are involved in the natural healing process of bone injury, has also been extensively investigated and accepted as a kind of therapeutic strategy in clinics [182]. It must be noticed that only a few biological factors, such as BMPs, fibroblast growth factors (FGF) vascular endothelial growth factors (VEGF), PTH and platelet-rich plasma (PRP), have undergone rigorous preclinical tests and clinical trials (see Table 2) [34].

3.4. Bone morphogenetic proteins (BMPs)

Bone morphogenetic proteins (BMPs), especially BMP-2 (including recombinant human BMP-2, rhBMP-2) and BMP-7 (including recombinant human BMP-7, rhBMP-7), are members of the transforming growth factor beta (TGF-β) superfamily with superior osteoinductive properties and are possibly the most extensively investigated growth factors in treating skeletal defects [34]. BMP-2 is able to induce osteoblastic differentiation from mesenchymal stem cells, and BMP-7 can directly promote angiogenesis. The largest trial in the use of BMPs was in treating open tibial fracture, naming the BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT), which involved multiple clinical centers [185]. In the trial, 450 patients were randomly divided into three groups, one group received BMP-2 at 0.75 mg/ml, the second group received 1.5 mg/ml and the third was the control group. An intramedullary nail was applied universally. Twelve months after surgery, quicker bone...
callus formation and wound closure with lower infection and less pain were displayed in the patients treated with 1.5 mg/ml rhBMP-2 compared to the control, which indicates the efficiency of BMP-2 in treating tibial open fractures but with a dosage dependent effect. In an earlier study by Friedlaender et al. [186], 124 tibial non-unions were fixed by an intramedullary rod before randomly receiving either rhBMP-7 in a collagen sponge or iliac crest autografting at revision surgery. Nine months later, 81% of patients in the rhBMP-7 group and 85% of those in the autograft group were able to bear full weight without significant pain. At a final follow-up of two years, no statistically significantly differences were observed between these two groups. The use of rhBMP-2 or rhBMP-7 soaked collagen sponge in treating tibial non-unions demonstrated results equivalent to autologous iliac crest grafting, while also reduces persistent donor pain. After being tested in numerous animal models [187] and clinical trials [188–191], rhBMP-2 (INFUSE™, Medtronic, US) has been approved by FDA and European Medicines Evaluation Agency (EMEA) for the application in anterior lumbar spinal fusion.

### Table 2

| Source | Receptors class/target cells | Functions | Clinical applications in orthopaedics |
|--------|-----------------------------|-----------|--------------------------------------|
| BMPs   | Osteoprogenitor cells, osteoblasts, bone extracellular matrix | Serine/threonine kinase receptors, stem cell and chondrocyte | Promotes differentiation of mesenchymal stem cells/ osteoprogenitor cells into chondrocytes and osteoblasts, influences skeletal pattern formation | rhBMP-2 is used for the treatment of anterior lumbar spinal fusion and open tibial fractures, and rhBMP-7 is used for posterolateral lumbar spine fusion |
| FGFs   | Macrophage, mesenchymal cells, chondrocytes, osteoblasts | Tyrosine kinase receptors | Mitogenic for mesenchymal stem cells, chondrocytes, and osteoblasts. Increases collagen deposition and angiogenesis [57] | |
| VEGF   | Platelets, chondrocytes in callus | Vascular endothelial cells | Increases angiogenesis and vascular development | |
| PTH    | Parathyroid glands | Stem cell, chondrocyte and osteoblast | Increased callus size, bone mass and mineral content | The full length PTH(1–84) and a segment, PTH(1–34), is used to increase the cancellous bone mass and reduce the risk of vertebral and non-vertebral fracture of patients with osteoporosis. Mainly applied in orthopaedics and sports medicine to help hemostasis and musculoskeletal healing [184] |
| PRP    | blood | Variety cell types | Cocktail of growth factors | |

Abbreviations: BMPs, bone morphogenetic proteins; FGFs, fibroblast growth factors; VEGF, vascular endothelial growth factor; [rh]PTH, (recombinant human)parathyroid hormone; PRP, platelet-rich plasma.
and open tibial fractures [59,181], while rhBMP-7 (OP-1™, Stryker, US) has received approval in treatment of postero-lateral lumbar spine fusion [190,191]. However, due to the lack of osteoconductivity, commercial available forms of BMPs are always combined with an osteoconductive carrier, such as collagen, allograft or even autologous bone graft, for the purpose of enhancing efficiency (see Fig. 3).

Triggers by the clinical evidence of quicker bone formation stimulated by BMPs, the off-label usage has increased dramatically, which was reported to account for 85% in lumbar fusion procedures in 2008 [192]. Other than the approval application in tibial nonunion, the investigations in treating other long-bone non-unions, such as humerus pseudarthrosis [193], lower limb pseudarthrosis [194–196], clavicle [197] and ulna [198], have also been reported sporadically, whereas results were found poor or with a very small level of evidence [199]. In a prospective and randomized clinical trial reported by Ekrol et al., in 2008 [200], 30 patients with symptomatic malunion of the distal radius received a corrective osteotomy, either autogenous iliac crest bone grafting (AICBG, 16 patients) or directly application of rhBMP-7 (without any carrier, 14 patients) was conducted randomly. Due to the loss of fixation, an external fixation system was applied in four patients from the rhBMP-7 group and six patients in AICBG group, respectively, before the internal fixation system was used in the remaining patients (10 patients in each group). Although this change makes the result difficult to explain, an inferior healing and union percentage was demonstrated in the group receiving rhBMP-7 treatment and it was believed that their results may have been significantly different if a carrier had been applied. Several researchers have also applied BMPs to improve the foot or ankle arthrodesis fusion in patients with poor surgical healing [201–203] and the effective adjuvant effect was exhibited [204], whereas randomized controlled trials are still missing.

After all, it is generally accepted that the equivalent clinical outcome would be achieved when using the BMPs to treat some complex bone defects, such as spine fusion and tibial open fracture, as compared to iliac crest autologous bone graft, whereas the high rate of complications is the concern [199]. BMPs are especially soluble proteins and have a tendency to dissipate from their intended locations [57] and lead to several complications. As demonstrated in the previous literature, there tends to be a dose dependent effect in the application of BMPs [205]. The dissipation of proteins would dilute their local concentration, and, in turn, their efficiency. In addition, BMPs can influence several cell types and organs, which subsequently cause heterotopic bone formation. Boraiah et al. reported 10 cases of ectopic bone formation out of 17 complex proximal tibia fracture treated with rhBMP-2; four of them needed extra surgical excision [206]. In some extreme conditions, such as one case reported by Ritting et al., the use of BMP-2 in an ulnar non-union in a nine year old patient led to a persistent inflammatory response and finally caused osteolysis [207]. Additionally, cost effectiveness is another important issue when using BMPs [208].

3.5. Fibroblast growth factors (FGFs)

There are 22 members of fibroblast growth factors family and 4 fibroblast growth factor receptors (FGFRs) being identified and are found secreted by monocytes, macrophages, mesenchymal stem cells, osteoblasts and chondrocytes, starting from the early stages of fracture healing and lasting throughout the whole healing process [209]. The role of FGFs in fracture healing is not well understood, but it has been demonstrated that FGFs not only play a critical role in angiogenesis [210–212] but also have potent mitogenic effects on mesenchymal progenitor cells [213], all of which are mediated by the FGFs/FGFRs signaling. Among all those FGFs and FGFRs, FGF1, FGF2 and FGRF1-3 were found closely related to bone regeneration by numerous studies [214–217], in which FGRF1 and FGRF2 have stronger expressions in osteoprogenitors and osteoblasts whereas FGRF3 is more related to chondrogenesis [218]. Hence, the efficiency of FGF2 in treating bone defect was investigated by numerous in vivo animal studies [219,220], including two non-human primate studies [221,222], and results also showed promoted fracture healing, whereas this effect is dose and time dependent [218,223]. One representative clinical trial of rhFGF in treating tibial shaft fracture in 70 patients was reported by Kawa-guchi et al. [224]. After fixation by an intramedullary nailing system, patients were randomly injected with either gelatin hydrogel (placebo, 24 patients) or 0.8 mg rhFGF-2 in gelatin hydrogel (low dosage group, 23 patients) or 2.4 mg rhFGF-2 in gelatin hydrogel (high dosage group, 23 patients) at the fracture site. Radiographically analysis demonstrated accelerated fracture healing and higher fracture union in both rhFGF treated groups compared to the hydrogel-only treated group, while no difference between the low dosage group and high dosage group was displayed. However, due to our limited understanding on the spatiotemporal expression patterns of FGFs/FGFRs signaling in fracture healing, further studies are still demanded before the clinical trial. In addition, the results of FGFs in treating bone fracture compared to autologous and BMPs are unavailable as well.

3.6. Vascular endothelial growth factor (VEGF)

Local vascularity at the fracture site has been recognized as one of the most significant parameters affecting bone regeneration, and the VEGF is a dominant pathway in the two main hormonal pathways controlling angiogenesis, the VEGF pathway and the angiopoietin pathway [225,226]. Except for angiogenesis, VEGF has also been demonstrated to be osteogenic [227]. In the bone fracture healing process, VEGF is initially released from hematoma and promotes the development of endothelial cells to induce vascular invasion [57] under the hypoxia environment [228]. Consequently, during the endochondral ossification process, VEGF is secreted by hypertrophic chondrocytes in the epiphyseal growth plate to promote the blood vessel invasion of cartilage and blood flow that facilitates new bone formation [229,230]. Numerous animal studies have shown the effectiveness of exogenous VEGF to promote bone fracture healing [231–235]. In one research reported by Kaigler et al. [232], rodents with critical sized cranial bone defect were treated by either bioglass alone or VEGF-containing bioglass. Increased vascularization and bone quality was observed in the VEGF-containing group but no significant difference was displayed when comparing the quantity of the newly formed bone. A similar result was documented in other research published from the same laboratory [233], which implied that VEGF tends to contribute to bone maturation but does not enhance the amount of new bone formation [227]. In a rabbit model, either VEGF or autograft, was compared to a carrier-alone group in treating experimental fracture non-unions [234]. Compared to the control group, significant new bone formation and enhanced mechanical properties were observed from a radiological evaluation and bio-mechanical testing, respectively, while no significant difference was demonstrated in the blood flow and vascularity. All the evidence supports the importance of the collaboration of angiogenesis and osteoinductive factors in bone regeneration [226]. Although the cornerstone role of VEGF in angiogenesis during fracture healing has been confirmed and promising bone regeneration outcomes have been demonstrated in preclinical research, VEGF is in fact very unstable and short-lived in vivo, so a gene delivery vehicle is usually employed. Additionally, concerning the risk of haemangiomias or
recurrence of tumors stimulated by VEGF, especially for those patients after radiotherapy or tumor excision, the application of VEGF in clinical trials and its direct effect on human fracture healing is strictly limited [235], and the application of VEGF must be very accurate in dosology [227].

3.7. Parathyroid hormone (PTH)

Parathyroid hormone (PTH) is a naturally occurring endocrine containing 84 amino acids and functions as a mediator of calcium and phosphate homeostasis in humans [237]. It has also been demonstrated to increase bone mass, bone strength and reduce bone loss, and the structure-function analysis of PTH has suggested that these activities are mainly attributed to the N-terminal fragment (encompassing amino acids 1–34 and called PTH(1–34)) [238]. Thus, there are two PTH-derived products available nowadays, the full length protein PTH(1–84), with a commercial name of Natpara™ (Shire-NPS Pharmaceuticals, US), and a segment of protein PTH(1–34), which was licensed by FDA in 2002 under the name of Teriparatide (Forteo™, Lilly LLC, US) [237], and they have been developed as drug to increase the cancellous bone mass and reduce the risk of vertebral and non-vertebral fracture of patients with osteoporosis. Although the exact mechanism is not fully understood, it was found that several signaling pathways were involved and the anabolic effect of PTH was exerted mainly through inhibiting the apoptosis of preosteoblasts, increasing osteoblast function and lifespan, thus leading to an increased number of these bone-making cells [239].

Driven by the fact that PTH increases bone mass and prevents fracture in osteoporotic bone [240], a growing number of studies have suggested the ability of PTH to accelerate fracture healing even though most of the studies were focused on animals. In a diaphysial femoral fracture model involving 270 male Sprague Dawley rats, either a placebo or 5 μg/kg or 30 μg/kg PTH (1–34) were injected daily subcutaneously for 35 days [241]. Significantly torsional strength, stiffness, bone mineral content, bone mineral density and cartilage formation were observed in the callus from the group treated with 30 μg/kg PTH compared to that from the control group over 21 days; no difference in osteoclast density was detected. Other animal experiments confirmed the positive effects of PTH on fracture healing in different species, locations and under various pathological conditions [242]. As a summary of these investigations conducted in animal model, it is confirmed that intermittent treatment with PTH has anabolic effects on bone and thus leads to recovery of bone mass and increased mechanical property, whereas continuous exposure to PTH are contrarily cause bone loss [238,243–246].

In 2010, Aspenberg et al. conducted a prospective, randomized clinical trial employing 102 postmenopausal women patients with distal radial fractures [247], and they were randomized to receive a placebo, 20 μg PTH daily (ordinary osteoporosis dosage) or 40 μg injection daily (double dosage). No such difference between 20 μg group and 40 μg group was found but a shorter time for the first radiographic evidence of cortical bridging was documented, which were 9.1, 7.4 and 8.8 weeks in the placebo, 20 μg group and 40 μg group, respectively. Further analysis demonstrated that PTH would mainly increase the early callus formation with a dose-dependent pattern, whereas the cortical bridging is not necessarily stimulated by PTH [248]. In another study involving pelvic ramus fractures in 65 osteoporotic women, radiographically bridging of cortical bone was found shortening from 12.6 weeks in the control group to 7.8 weeks in the PTH(1–84)-treated group [249]. More recently, the effect of Teriparatide in treating elderly patients with a pterroaneteric hip fracture was compared to those using risedronate, which is a bisphosphonate drug, in a randomized clinical trial [250,251]. In 171 patients, 86 received 20 μg Teriparatide every day and others received 35 mg risedronate once per week, started within 2 weeks after surgery. Seventy-eight weeks later, several outcomes, including the BMD at the lumbar spine (LS), femoral neck (FN) and total hip (TH), functionality (through timed up-and-go (TUG) test), hip pain (Charnley score and 100 mm visual analog scale (VAS)), quality of life, radiology outcomes and safety, were comprehensively analyzed. Significantly greater increasing LS and FN BMD, less pain and a faster TUG results were recorded when patients were treated with Teriparatide as compared to those with risedronate [251]. Conclusively, there is little doubt that PTH has positive influence on fracture healing, but it must be noticed that PTH is not a differentiation factor and is unlikely to help if fracture healing is not started properly. Additionally, the robust evidence observed in animal studies has not been demonstrated beyond a reasonable doubt in humans [238].

3.8. Platelet-rich plasma (PRP)

The investigation of platelet-rich plasma (PRP) for bone regeneration represents attempts to harness the power of the cascade of growth factors released by the aggregation and degranulation of platelets in the native fracture haematoma [252]. PRP is mainly produced by isolating and concentrating platelets from peripheral blood with commercially available devices. It is the plasma fraction of autologous blood having a platelet concentration above baseline [253]. It contains various key mitogenic and chemotactic factors that include platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), fibroblast growth factors (FGFs), transforming growth factor-beta (TGF-β) and VEGF [254]. For those patients receiving conservative orthopaedic treatment caused by aging and degeneration, such as knee pain and tennis elbow, PRP are frequently used and demonstrate good clinical outcomes [255–257]. However, when investigating the effect of PRP on bone healing, especially in human bone healing, the clinical results are conflicting and strong supportive evidence is lacking [59]. In 2008, Calori et al. conducted a prospective, randomized trial comparing the treatment effect of rhBMP-7 and PRP in 120 patients with long bone non-unions [258]. They found a union occurring in 68.3% of cases (41 of 60 patients) in the PRP treated group while the number was 86.7% (52 of 60 patients) in the rhBMP-7 group. The mean time to clinical healing was four months in the PRP group compared to 3.5 months in the rhBMP-7 group. These results implied significantly inferior healing when treated with PRP. Another study investigated the efficacy of PRP in the treating 132 patients with delayed union after when the long bone fractures were surgically intervened at the Military Medical Institute in Warsaw between 2009 and 2012 [259]. Bone union was established in 108 patients (81.8%) after PRP administration, whereas 24 patients (18.2%) showed no improvement. They also concluded the location-dependent efficiency of PRP since 100% union (on average of 3.5 months) was exhibited at proximal tibial, whereas the union at proximal humerus was only 63.64% (on average of 3.2 months). The efficacy of PRP in treating nonunion of long bone can also be found in a more recently report involving 94 patients [260]. Autologous PRP (> 2,000,000 platelets/μL) with a dose of 15–20 mi was directly injected to the defect sites and the bridging was radiologically evaluated by X-ray at monthly interval till 4 months. Eighty-two patients (87.23%) had their fracture union at the end of 4 months and no complication was documented. Nonetheless, the negative effect of PRP on bone healing was not rare [261,262]. Ranly et al. reported that PRP may inhibit bone formation through the prevention of osteosinduction in mice models [263,264]. In these limited number of human clinical trials involving the usage of PRP in treating orthopaedic defects, faster bone healing
was demonstrated, whereas its efficacy was still inferior to BMPs. Nevertheless, it is still insufficient evidence to support its routine use in orthopaedic trauma and well-planned, randomized control trials are still needed [265,266]. Meanwhile, it must be noticed that the platelet activity is influenced by many factors related to the individual whose blood is being collected [267], and therefore the standardized concentration and biological quantification of PRP in treating bone healing requires further studies.

3.9. The adoption of bioinorganic ions on bone regeneration

Triggering by some negative attentions and adverse events regarding the off-label usages of growth factors, safety issue has become a concern [11,13,268]. Alternatively, incorporation and/or local delivery of bioinorganic ions, which is also a natural but safer approach, has been highlighted [269]. Inspired by observing nutritional deficiency or excess, bioinorganic ions have long been applied in a variety of therapies even when little was known of their mechanisms [19]. In past few years, the role of metallic ions in the human body had been unraveled gradually (see Table 3 and Fig. 4). Bioinorganic ions, such as silicon, magnesium, strontium, zinc and copper, can still be regarded as essential cofactors of enzymes, coenzymes or prosthetic groups. Additionally, they are actively involved in ion channels or in the process of secondary signaling either on direct stimulation or as an analog [19]. Additionally, incorporation of these ions confers low cost, longer shelf life and perhaps lower risk compared to growth factors [270]. The therapeutic use of bioinorganic ions, especially some heavy metal ions, seems counter-intuitive, but the words of Paracelsus are pertinent: ‘Everything is poisonous and nothing is non-toxic, only the dose makes something not poisonous’ [271]. Consequently, the challenge in using bioinorganic ions in bone healing is also quite clear and has been described succinctly by Ash and Stone: ‘it is indeed a narrow path between poison and nutrition’ [272].

3.10. Magnesium (Mg)

Magnesium is the fourth most abundant cations in the body [293], equal to about 1 mol (24 g) in an adult human body [294] and over 60% is accumulated in bone and teeth [295]. Further studies documented that the majority of Mg that accumulates in bone tissue is concentrated on the hydrated surface layers of apatite crystals instead of incorporated into the lattice structure of bone crystals as showed in Fig. 5. This would allow rapid exchange of Mg\(^{2+}\) between blood and extracellular fluid, leading to ion homeostasis [296–298]. As an essential element in the human body, magnesium has been found to be cofactor for various enzymatic reactions involved in energy metabolism, protein and nucleic acid synthesis, functional maintenance of parathyroid glands and vitamin D metabolism that are strictly related to bone health [299,300]. Several researchers studying the effect of a Mg-depleted diet on rats showed decreased systemic bone density [301], inhibition of growth in the proximal end of the tibia [302] and even development of osteoporosis [303]. Meanwhile, a higher intake of magnesium has been proved to efficiently prevent reduction of bone mineral density (BMD) in patients with osteoporosis [304]. On

Table 3

| Role | Mechanism of action | Documented efficiency dosage |
|------|---------------------|------------------------------|
| Mg\(^{2+}\) Osteogenesis, angiogenesis, neural stimulation | Magnesium induces HIF and activates PGC-1α production in undifferentiated and differentiated hBMSCs, respectively. This stimulates the production of VEGF. Mg\(^{2+}\) enters into DRG neurons and promotes the release of CGRP and then stimulates the PDSCs to express the genes contributing to osteogenic differentiation. | Mouse pre-osteoblasts and hTMSCs, 50–150 ppm [274–276]; human BMSCs, 5–10 mM [277,278] |
| Sr\(^{2+}\) Osteogenesis | Strontium promotes the activity of bone-forming osteoblastic cells, while inhibiting the bone resorbing osteoclasts. It activates CaSR and downstream signaling pathways. It increases the OPG production and decreases RANKL expression. This promotes osteoblast proliferation, differentiation, and viability and induces the apoptosis of osteoclasts that result to the decrease of bone resorption. | Rat BMSCs and primary osteoblasts, less than 1 mM [279,280] |
| Si\(^{4+}\) Angiogenesis, osteogenesis | Silicon has been shown to induce angiogenesis by upregulating NOS leading to increased VEGF production at low concentration when cultured with human dermal fibroblasts. Osteogenic mechanism is not well understood. However, Si\(^{4+}\) at higher concentration has been shown to play a vital role in the mineralization process. | Mg-63, HCC1 and human osteoblast-like cells: 10–20 μM [281]; human MSCs: less than 100 μg/mL [282] |
| Zn\(^{2+}\) Osteogenesis | Zinc is found to get involved in the structural, catalytic or regulation of ALP expression in which it plays an important role in osteogenesis and mineralization. It is also believed that zinc is able to suppress the osteoclastic resorption process. | Mouse Pre-osteoblast: 10^{-5}M [283–285]; Rat BMSCs: 10^{-5}M [286] |
| Cu\(^{+}\) Angiogenesis, Osteogenesis | Copper is reported to be a hypoxia-mimicking factor leading to the induction of angiogenesis. The immune microenvironment induced by Cu\(^{+}\) may indirectly lead to robust osteogenic differentiation of BMSCs via the activation of Oncostatin M (OSM) pathway. | Human BMSCs: less than 50 ppm [287]; mouse pre-osteoblasts: less than 50 ppb [288] |
| Li\(^{+}\) Osteogenesis | Lithium is able to inhibit the GSK3 expression, which is a negative regulator of the Wnt signaling pathway. Other investigations demonstrated that lithium is able to improve fracture healing by serving as an agonist of Wnt/β-catenin signaling. | Mice: 0.02M daily in drinking water [289] |
| Co\(^{2+}\) Angiogenesis | Co\(^{2+}\) ion is believed to induce the formation of hypoxia cascade, with which stabilizing HIF-1α. Then, the cells will compensate this hypoxic environment by expressing genes (such as VEGF and EPO) that promote neovascularization and angiogenesis. | Human BMSCs: 100 μM [290], 20 mg/L [291,292] |

Abbreviations: VEGF, vascular endothelial growth factor; CaSR, calcium sensing receptor; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor kappa beta ligand; NOS, nitric oxide synthase; ROS, reactive oxygen species; GSK3, glycogen synthase kinase 3; HIF-1α, hypoxia-inducible factor-1α; EPO, erythropoietin; hTMSCs, human TERT-immortalized mesenchymal stem cells; BMSCs, bone marrow stem cells; ALP, alkaline phosphatase.
the contrary, toxic symptom induced by magnesium excess is rarely being reported since the Mg concentration is strictly mediated by the kidneys through urine excretion [299].

Our previous studies [274,275] suggested that when magnesium ion concentration fell in an appropriate range (i.e. 50–100 ppm), it was able to up-regulate the viability of mouse pre-osteoblasts. The specific alkaline phosphate (ALP) activity of osteoblasts cultured with Mg ions supplemented media was found to be significantly higher compared with the control. The real-time RT-PCR study also exhibited higher levels of ALP and runt-related transcription factor-2 (Runx2) expression after stimulation with a suitable amount of Mg ions. The highest levels of Type I collagen (Colla 1) and osteopontin (Opn) expression were found on Day 3 from the cells cultured with a conditioned medium. In other research, magnesium was doped into various kinds of materials, including hydroxypatite, tricalcium phosphate and collage, and the biological activities of those materials were investigated and compared to a non-doped control. Interestingly, when the apatite in the collagen was totally replaced by magnesium, a toxic effect was demonstrated and the formation of extracellular matrix (ECM) was inhibited [306]. However, when the amount of magnesium being doped was controlled in a suitable range [307], densification as well as osteoblastic cellular attachment, proliferation and ALP production improved [277,278,308], greater osteogenic properties were also observed in vivo [309]. Meanwhile, the osteoclast formation, polarization, and osteoclast bone resorption was suppressed in vitro [310]. These results are similar to the observations in our previous in vivo studies. High dosage (high-Mg/PCL, 0.6 g Mg in 1 g PCL), low dosage (low-Mg/PCL, 0.1 g Mg in 1 g PCL) Mg/PCL and pure PCL were implanted at the lateral epicondyle of rats. Superior newly formed bone was observed in the low-Mg/PCL group after two months, whereas bone regeneration in the high-Mg/PCL group was even worse than that in control (unpublished data). These phenomena again highlight the importance of dosage when utilizing magnesium in bone healing.

Although the mechanism of magnesium ions on fracture healing is not yet fully explained, recent investigations are bridging this gap. Research conducted by S Yoshizawa et al. [277,278] conjectured that the osteo-regenerative effect of Mg$^{2+}$ on undifferentiated human bone marrow stromal cells (hBMSCs) and osteogenic hBMSCs was likely attributed to the subsequent orchestrated
responses of activating hypoxia-induced factor 2α (HIF-2α) and peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α), respectively. The hypothesized intracellular signaling cascades were exhibited in Fig. 6. J Zhang et al. found that the rat bone marrow stem cells (BMSCs) depicted significantly upregulated integrin α5β1 expression when cultured with 5% Mg-incorporated calcium phosphate cement (5MCPC) and thus promoted the osteogenic differentiation, whereas this effect was not observed when cultured with 10MCPC and 20MCPC[312]. More recently, YF Zhang et al. demonstrated that the magnesium ions may stimulate the accumulation of neuronal calcitonin gene-related polypeptide-α (CGRP) in both the peripheral cortex of the femur and the ipsilateral dorsal root ganglia (DRG) and thus promoted the fracture healing in rat animal model and the mechanism was elucidated in Fig. 7[311]. This research revealed an undefined role of Mg2+ in CGRP-mediated osteogenic differentiation. In another research, while investigating the long-term in vivo degradation mechanism of Mg alloy, JW Lee et al. found that the existence of Mg may facilitate the crystallization of calcium phosphate in a rabbit femoral condyle defect model [313]. All these recent findings again highlighted the importance of magnesium in fracture healing and suggest the therapeutic potential in orthopaedic clinics.

3.11. Strontium (Sr)

Strontium is a bone-seeking element, 98% of which can be found in the skeleton[314]. It accounts for 0.035% of mineral content in the skeleton system[270]. Its size and behavior are similar to calcium as they are in the same periodic group. As a non-essential element, a clinical case regarding the deficiency of strontium is rare but the over feeding of strontium in rats produced rickets by disrupting calcium absorption, vitamin D synthesis and subsequent mineralization[315]. The detailed mechanism is predicted to being attributable to the similarity between strontium and calcium, which allows Sr to share some osteoblast-mediated processes dominated by calcium in bone metabolism as showed in Fig. 8. Briefly, strontium activates the calcium sensing receptor (CaSR) in osteoblast[316,317] to stimulate the production of osteoprotegerin (OPC)[318,319], which subsequently suppresses the expression of the receptor activator of nuclear factor kappa beta ligand (RANKL), thus inhibiting RANKL-induced osteocalcitogenesis[320]. In one in vitro experiment, rats bone marrow mesenchymal stem cells (BMMCs) were cultured in an osteogenic medium supplemented with 0.1 or 1 mM Sr2+ (8.7 mg/L or 87 mg/L) for two weeks.
Proliferation of BMMCSs was significantly inhibited, while osteoblastic differentiation was promoted dose-dependently [280]. In another cell culture experiment, the dose-dependent effects of strontium on rat primary osteoblasts in terms of nodule formation and mineralization were observed compared to the Sr-depleted control. In the conditioned medium supplemented with a low dosage of Sr (0.5 and 1 μg/mL), nodule formation was reduced, while mineralization was intact. In the conditioned medium supplemented with an intermediate dosage of Sr (2 and 5 μg/mL), neither of these processes was affected. In the conditioned medium supplemented with high dosage of Sr (20 and 100 μg/mL), nodule formation was not affected but mineralization was reduced, indicating that the formation of hydroxyapatite was inhibited [279]. Meanwhile, the ability of the strontium to reduce bone resorption [321] and osteoclast activity [322] was also observed when cultured with rat osteoclasts and primary mature rabbit osteoclasts, respectively. Given the dual roles of strontium on bone formation, one strontium salt, strontium ranelate, has been utilized clinically as a prescriptive treatment for postmenopausal women with osteoporosis in Europe [323].

Attempts have also been made to incorporate strontium into synthetic mineral ceramics; mechanisms may involve an exchange with ions on an apatite surface or heteroionic substitution [325]. Data showed that tricalcium phosphate was able to host up to 20 wt.% of strontium [326,327] and the number was 12 wt.% in hydroxyapatite [328,329], without provoking rearrangement of the unit cell. The biological activity of those strontium-substituted mineral ceramics has been documented in numerous studies, demonstrating pronounced apatite layer formation [330], increased attachment, proliferation and differentiation when cultured with osteoprecursor cells [331] and human osteoblasts MG-63, and suppressed osteoclasts proliferation [332]. Similar results were

Fig. 8. (A) A schematic showing the dual mechanism of action of strontium (Sr): the stimulatory role on bone-forming osteoblast cells and the inhibitory role on bone resorbing osteoclast cells. (B) A schematic showing how Sr activates osteoblastogenesis. Abbreviations: CaSR, calcium sensing receptor; ERK1/2, extracellular signal-regulated kinases 1/2; P38, a mitogen-activated protein kinases; PLC, phospholipase C; PKD, protein kinase D; P38K, phosphatidylinositide 3-kinases; PKCaII, protein kinase C [III]; NF-kB, nuclear factor kappa beta; NFATc, nuclear factors of activated T cells; PGE2, prostaglandin E2; FGFR, fibroblast growth factor receptor (Reprinted from Refs. [270,324], Copyright (2013, 2012), with permission from Elsevier).
displayed in animal studies [333–335]. Enhanced new bone formation was presented on the surface of strontium-containing mineral ceramics, while resorptive activity of osteoclasts was inhibited. Nevertheless, while analyzing these in vivo characterizations, it must be noted that strontium substitution not only releases Sr²⁺ into the microenvironment but also alters the other physico-chemical properties, and these effects cannot be isolated from the final results.

Recently, concerns about the adverse side effect of strontium ranelate in patients with established, current or history of cardiovascular events and venous thrombosis has been highlighted [336]. In 2013, increased risk of myocardial infarction in postmenopausal women was reported when using strontium, thus leading to the suspension of this drug [337]. More importantly, this drug has not yet been approved by the FDA so far.

3.12. Silicon (Si)

Silicon is the second most abundant element on earth, and since silicate (a silicate is a silicon-containing anion) is rich in foods and water, deficiency in humans is rare and its pathology is unknown. But in an animal model, chickens on a silicon-depleted diet showed delayed bone development, low collagen formation and stunted growth [338]. Research found that silicon is rich in bone and connective tissue as an integral component of glycosaminoglycan and their protein complexes [339], which may subsequently affect bone formation and maintenance [340]. In research performed by Carlisle, an electron micro-probe was applied to locate silicon in the tibial bones of young mice and rats. Silicon was detected in the early conditions, and diminishing when the mineral composition approached hydroxyapatite [341]. These observation have confirmed that silicon is associated with calcium in bone metabolism [342].

While testing the effect of aqueous silicon on cellular activity, dose-dependent enhancement of osteoblast proliferation, differentiation and collagen production were observed in vitro [281,343]. Human osteoblast cells demonstrated 1.8-, 1.5- and 1.2-fold increases in type I collagen, alkaline phosphatase and osteocalcin activity, respectively, when cultured with a conditioned medium supplemented with 0–1.4 ppm (50 µM Si) of orthosilicic acid [281]. In another study, human osteblast-like cell was incubated with 0.1–100 ppm (3.6 mM) Si for 48 h, and a dose-dependent increase in proliferation and osteogenic differentiation mediated through up-regulation of transforming growth factor beta (TGF-β) was reported [343]. In a recently published paper [282], bioactive silicate nanoplatelets with a concentration of 100 µg/ml triggered osteogenic differentiation of human mesenchymal stem cells (hMSCs) without any osteoinductive factor, and this effect dropped when the concentration exceeded 1 mg/ml (Fig. 9). However, the mechanism of inducing osteogenic differentiation of hMSCs is not fully explained. In numerous bone healing investigations involving the application of Si-substituted CaPs, including Si-HA and Si-TCP, superior biological performance of their stoichiometric counterparts has been documented [344]. However, a critical review pointed out that no direct evidence can link the improved biological performance of Si-substituted CaPs to the released Si [342], since the substitution of silicon not only alters the Si release but may also change the dissolution rate of ceramics [345,346], grain size in structural composition [347,348], protein conformation at the material surface [349], or surface topography [348,350]. As a kind of silica based synthetic bone substitute widely used in orthopaedic applications, bioglass can't be ignored when discussing the effect of silicon on bone regeneration. As mentioned before, it is speculated that the bioactivity of bioglass is attributed to the leaching and accumulating of silicon ions when exposed to body fluids upon implantation, and the subsequently formation of hydroxyapatite coating on the surface [152]. Nevertheless, it is accepted that the hydroxyapatite coating, but not the leaching silicon ions, played an active role in the processes leading to new bone formation [19].

3.13. Zinc (Zn)

Zinc is also an essential trace element in the human body with total weight at about 1.4–2.3 g and this number is between 150 and 250 µg/g in bone ash (0.015–0.025 wt.%), which is higher than other tissues [351]. It is involved in the structural, catalytic or regulatory action of several important metalloenzymes and alkaline phosphatase (ALP) is among them. It was found that ALP not only generate phosphates by hydrolyzing pyrophosphates, but they also created an alkaline environment that favored the precipitation and subsequent mineralization of these phosphates onto the extracellular matrix, which were produced by osteoblasts [270]. As far as we know, ALP is a zinc enzyme with three closely spaced metal ions (two Zn ions and one Mg ion) presented at the active center [352]. Further investigations suggested that inactivation of ALP activity is caused by the dissociation of an active center Zn, and preventing the dissociation of this active center Zn can stabilize the enzyme and increase its half-life [353]. Given its important role in skeleton system, zinc deficiency is reported to be associated with decreased bone age [19], whereas high zinc level may lead to hypocupremia by retarding the intestinal absorption of copper [354]. These findings are coincident with some cell culture experiments. Yamaguchi et al. [283] showed significantly increased Runx2, OPG and regucalcin mRNA expressions in osteoblastic MC3T3-E1 cells when zinc supplementation was in the concentration of 10⁻⁵ to 10⁻⁴ M (0.65 mg/L to 6.5 mg/L). Kwun et al. [284] observed a negative effect of zinc deficiency on the osteogenic activity of the same cell type, bone marker gene transcription and ECM mineralization were reduced through inhibited and delayed Runx2 expression and inhibition of ALP activity in osteoblasts, respectively. However, these regulation effects were not displayed when cultured rat bone marrow stem cells with Zn²⁺ were supplemented (1*10⁻⁵ and 4*10⁻⁵ M, eq. to 0.65 mg/L and 2.6 mg/L) osteogenic medium [286]. Suppression effects of zinc on bone resorption and osteoclastogenesis from bone marrow derived osteoclasts were recently shown in the tissue culture system [355].

Zinc has also been found to stabilize the crystal lattice of β-tricalcium phosphate, thus making the dissolution of TCP predictable and complete [326]. In the rabbit femoral defect model, zinc-containing HA/TCP with a high concentration (about 0.6 wt.%, high-Zn-HA/TCP) or low concentration (about 0.3 wt.%, low-Zn-HA/ TCP) was applied. Low-Zn-HA/TCP demonstrated increased bone apposition, and high-Zn-HA/TCP led to increased resorption of the host bone [356]. However, in another in vitro study, ceramics containing 0.6 wt.% of zinc displayed inhibited resorptive activity in mature osteoclasts [357]. Still, the boundary between the in vitro studies and in vivo assessments are huge, and controversial results are reported.

3.14. Copper (Cu)

Copper is an essential element, and 90% of copper in plasma is presented in ceruloplasmin [19]. Copper's function in human body was firstly identified in iron metabolism and copper deficiency usually leads to iron overload in brain, liver and other tissues [358]. Later on, copper has been recognized as a cofactor for several other enzymes in body, one of which related to the musculoskeletal system is lysyl oxidase, an enzyme that catalyzes the formation of
aldehyde-based crosslinks from lysine residues in collagen and elastin precursors [19]. Consequently, 300% higher collagen solubility was found to lead to copper-deficiency and brittle bone [359]. Recently, being discovered as an essential element in angiogenesis [360] and to initiate endothelia cells towards angiogenesis [361,362], the application of copper ions as an alternative therapeutic agent in promoting vascularization has attracted increasing attentions [362–365]. Since vascularization plays a critical role in bone healing [37], it is reasonable to conduct relevant research. Several studies have demonstrated rapid and enhanced vascularization in copper-doped porous scaffolds and increased extracellular matrix (ECM) formation, and the collagen formation in turn supports further blood vessel formation in vivo physically [366,367]. Interestingly, instead of utilizing the traditional biomaterial-assisted concept, which is to accelerate bone ingrowth from the periphery, copper-doped biomaterials demonstrated a tendency to accelerate bone formation throughout the defect, which is likely attributed to angiogenic effect of Cu$^{2+}$ [19]. Lately, copper ion has been predicted to positively affect osteogenic differentiation of bone marrow stem cells [287,368] and mouse MC3T3-E1 preosteoblasts [288] when being doped into mesoporous silica nanosphere and stainless steel, respectively. Nevertheless, excess copper can lead to serious disease in the liver and neurological issues [369,370]. Again, dosage is critical.

Fig. 9. Effect of silicate nanoplatelets on hMSCs differentiation. a) The addition of silicate nanoplatelets upregulate alkaline phosphatase (ALP) activity of hMSCs. b) The increase in the RUNX2 (green) and production of bone-related proteins such as osteocalcin (OCN, green), and osteopontin (OPN, red) was observed due to the addition of silicates. Cells in normal media without silicate particles act as a negative control whereas cells in osteoinductive medium serve as a positive control. Cell nuclei were counterstained with DAPI (blue). c) The protein production was quantified using image analysis from the fluorescence images. The intensity of protein per cell was quantified and later normalized by the control (hMSCs in normal growth media with no silicate particles) to obtain a fold-increase in the production of protein (Reprint with permission from Ref. [282]).
3.15. Other ions

Lithium (Li) has attracted attention due to its role in osteogenesis [270]. A study involving 75 lithium-treated patients reported that the mean bone mineral density in several areas in a treated group was significantly higher than normal participants; this was possibly due to a lower bone turnover in lithium-treated patients [371]. Another case control study compared 231,778 fracture cases and found that the current use of lithium showed a decreased risk of fracture, while an increased risk of fracture was observed among past users [372]. The mechanism of lithium behind osteogenesis is predicted by inhibiting glycogen synthase kinase 3 (GSK3), which is a negative regulator of the Wnt signaling pathway [373,374]. In addition, Li⁺ has been shown to activate β-catenin signaling by mediating osteoblast proliferation, differentiation and maturation [375], during bone and cartilage fracture healing [289].

Co [302] Cobalt (Co) is an integral part of vitamin B12, which stimulates the production of red blood cells [273]. Like copper, cobalt was recently showed to stimulate angiogenesis [270]. Significantly upregulated VEGF was expressed when bone marrow stem cells were treated in a 100 μM CoCl₂ supplemented culture medium, and these CoCl₂-treated cells subsequently promoted vascularization, and osteogenesis when implanted in vivo with a collagen scaffold [290]. This effect was recently found to associate with the hypoxia-mimicking capacity of Co ions. Studies demonstrated that mesoporous bioactive glass (MBG) scaffolds doped with suitable amount of cobalt induce the hypoxia cascade, with which the hypoxia inducible factor-1 (HIF-1) was activated [291] and stabilized [292], and this increased the expression of HIF-α target genes, such as VEGF and erythropoietin (EPO) [376], thus leading to a higher degree of vascularization.

4. Conclusion

Orthopaedics scenarios such as large segmental bone defect may result in delayed union or even non-union if improperly treated clinically. Hence, surgical interventions together with bone grafting techniques are usually necessitated in the treatment process. Even though the emergence of various synthetic bone substitutes offers diversity options, the treatment outcome is still incomparable to the approach of autologous bone graft in terms of bone healing quality and time. One of the reasons leading to inferior bone regeneration when synthetic substitutes used is due to the lack of osteoinductivity. The incorporations of recombinant human growth factors (e.g. rhBMP-2) with bone allograft and other substitutes have been considered and widely applied in clinics. Their clinical outcomes have been extensively reported as well. The treatment efficiency has been approved though. The post-operative complications, the controversy of off-label applications and high application cost have been also documented. The complications may attribute to the uncontrolled release of growth factor that collaterally interfere the un-targeting cells. Alternatively, the incorporation of bioorganic ions such as magnesium, strontium, silicon, copper and cobalt into bone graft materials provides an economic and feasible solution for bone defect healing. Hopefully, the safety issue of these bioorganic ions used has been addressed by a number of studies in these years. When therapeutic effect and working mechanism of these ions have been clearly understood, human clinical trial can be possibly implemented. With more new discoveries, bioorganic ions can be considered to apply in the combination of growth factors for bone defect treatment that may induce synergistic effect in terms of new bone formation.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

This work was supported in part by Shenzhen Science and Technology Innovation Funding JCYJ201401409548118, JCYJ20160429190821781 and JCYJ2016429185449249, Hong Kong Research Grant Council General Research Funds (RGC GRF) (Nos. 718913E, 17214516, N_HKU725156), HKU Seedling Fund (Nos. 201511160001 and 201411159045), Hong Kong Innovation Technology Fund (No. ITS/147/15), Hong Kong Health and Medical Research Fund (No. 03142446), National Natural Science Foundation of China (NSFC) (Nos. 31370957).

References

[1] R.A. Bhatt, T.D. Rozental, Bone graft substitutes, Hand Clin. 28 (2012) 457–468.
[2] A.S. Greenwald, S.D. Boden, V.M. Goldberg, M. Yaszemski, C.S. Heim, in: Bone-graft Substitutes: Facts, Fictions and Applications, AAOS 75th Annual Meeting, 2008.
[3] R. Dimitriou, E. Jones, D. McGonagle, P.V. Giannoudis, Bone regeneration: current concepts and future directions, BMC Med. 9 (2011) 66.
[4] V. Campana, G. Milano, E. Pagano, M. Barba, C. Ciccone, G. Salonna, W. Lattanzi, G. Logroscino, Bone substitutes in orthopaedic surgery: from basic science to clinical practice, J. Mater. Sci. Mater. Med. 25 (2014) 2445–2461.
[5] T.W. Bauer, G.F. Muschler, Bone graft materials: an overview of the basic science, Clin. Orthop. Relat. Res. 371 (2000) 10–27.
[6] W.C. de Long, T.A. Einhorn, K. Koval, M. McKee, W. Smith, R. Sanders, T. Watson, Bone grafts and bone graft substitutes in orthopaedic trauma surgery: a critical analysis, J. Bone Jt. Surg. Am. 89 (2007) 649–658.
[7] Y. Fillingham, J. Jacobs, Bone grafts and their substitutes, Bone Jt. J. 98 (2016) 6–9.
[8] C.F.D. Control, Transmission of HIV through bone transplantation: case report and public health recommendations, MMWR Morb. Mortal. Wkly. Rep. 37 (1988) 597.
[9] S. Stevenson, M. Horowitz, The response to bone allografts, J. Bone Jt. Surg. 74 (1992) 939–950.
[10] A.A. Jahangir, R.M. Nunley, S. Mehta, A. Sharan, t.W.H.P. Fellows, Bone-graft substitutes in orthopaedic surgery, AAOS, 2008.
[11] GlobalData, MediPoint: Bone Grafts and Substitutes - Global Analysis and Market Forecasts, 2014.
[12] T. Kurien, R.G. Pearson, B.E. Scammell, Bone graft substitutes currently available in orthopaedic practice: the evidence for their use, Bone Jt. J. 95-b (2013) 583–597.
[13] FDA, Life-threatening Complications Associated with Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion, FDA Public Health Notification, July 1, 2008.
[14] FDA, AMPLIFY™ rhBMP-2 Matrix: Orthopaedic and Rehabilitation Devices Advisory Pannel Presentation, July 27, 2010.
[15] M.D. Hoffman, C. Xie, X. Zhang, D.S. Benoit, The effect of mesenchymal stem cells delivered via hydrogel-based tissue engineered periosteum on bone allograft healing, Biomaterials 34 (2012) 8887–8898.
[16] T. Long, Z. Zhu, H.A. Awad, E.M. Schwarz, M.J. Hilton, Y. Dong, The effect of mesenchymal stem cell sheets on structural allograft healing of critical sized femoral defects in mice, Biomaterials 35 (2014) 2752–2759.
[17] K.S. Griffin, K.M. Davis, T.O. McKinley, J.D. Anglen, T.M.G. Chu, J.D. Boerckel, M.A. Kacena, Evolution of bone grafting: bone grafts and tissue engineering strategies for vascularized bone regeneration, Clin. Rev. Bone Min. 13 (2015) 232–244.
[18] S. Bhumiiranata, J.C. Bernhard, D.M. Alfi, K. Yeager, R.E. Eton, J. Bova, J.M. Gimble, M.J. Lopez, S.B. Eisig, G. Vunjak-Novakovic, Tissue-engineered autologous grafts for facial bone reconstruction, Sci. Transl. Med. 8 (2016), 343ra383-343ra383.
[19] P. Habibovic, J.E. Barralet, Bioinorganics and biomaterials: bone repair, Acta Biomater. 7 (2011) 3013–3026.
[20] E. Seeman, Modeling and remodeling, in: J.P. Bilezikian, L.G. Raisz, T.J. Martin (Eds.), Principles of Bone Biology, Academic Press, 2008, pp. 3–28.
[21] A.K. Nair, A. Gautieri, S.W. Chang, M.J. Buehler, Molecular mechanics of mineralized collagen fibrils in bone, Nat. Commun. 4 (2013) 1724.
[22] I. Jager, P. Fratzl, Mineralized collagen fibrils: a mechanical model with a staggered arrangement of mineral particles, Biophys. J. 79 (2000) 1737–1746.
[23] H.S. Gupta, J. Seto, W. Wagemaker, P. Zaslansky, P. Boesecze, P. Fratzl, Cooperative deformation of mineral and collagen in bone at the nanoscale, Proc. Natl. Acad. Sci. 103 (2006) 17741–17746.
VEGF producing bone marrow stromal cells (BMSC) enhance vascularization and resorption of a natural coral bone substitute, Bone 41 (2007) 516–522.

[212] R. Eckardt, Z. Wang, K. Gao, Y. Mooney, VEGF scaffolds enhance angiogenesis and bone regeneration in irradiated osseous defects, J. Bone Miner. Res. 21 (2006) 735–744.

[213] L.J. Kent, K. Darnell, W. Zhuo, P.H. Krebsbach, D.J. Mooney. Coating of VEGF-releasing scaffolds with BMP-2 and angiogenesis for bone regeneration, Biomaterials 27 (2006) 3249–3255.

[214] H. Eckardt, M. Ding, M. Lind, E.S. Hansen, K.S. Christensen, I. Hvid, Reconstituent human vascular endothelial growth factor enhances bone healing in a rabbit model, J. Biomed. Mater. Res. 87 (2008) 1434–1438.

[215] J.R. Garcia, A.Y. Clark, A.J. Garcia, Integrin-specific hydrogels functionalized with VEGF for vascularization and bone regeneration of critical-size bone defects, J. Biomed. Mater. Res. 104 (2016), 1845.

[216] K.D. Hankenson, M. Gaylor, C. Gray, M. Schenker, Angiogenesis in bone regeneration, Injury 42 (2011) 556–561.

[217] S. Babu, N.A. Sandiford, M. Vahias, Use of Teriparatide to improve fracture healing: what is the evidence? World J. Orthop. 6 (2015) 457–461.

[218] A. Per, Annotation: parathyroid hormone and fracture healing, Acta Orthop. 84 (2013) 4–6.

[219] R.L. Jilka, Molecular and cellular mechanisms of the anabolic effect of intermittent PTH, Bone 40 (2007) 1434–1444.

[220] R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsim, E.F. Eriksen, S. Ish-Shahol, K.H. Genant, Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis, J. Med. Genet. 34 (2001) 1434–1441.

[221] Y.M. Alkhayri, L.C. Gerstenfeld, K. Elizabeth, W. Michael, S. Masahiko, B.H. Miltak, T.A. Einhorn, Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH) 1–34, J. Bone Jt. Surg. Am. 87 (2005) 731–741.

[222] S. Ralf, A. Per, Parathyroid hormone—a drug for orthopedic surgery? Acta Orthop. Scand. 75 (2004) 654–662.

[223] T. Wronski, C.-F. Yen, H. Qi, L. Dann, Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats, Endocrinology 132 (1993) 823–831.

[224] C. Jerome, D. Burr, T. Van Bibber, J. Hock, R. Brommage, Treatment with human parathyroid hormone (1–34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis), Bone 28 (2001) 150–159.

[225] M. Sato, M. Westmore, Y.L. Ma, A. Schmidt, Q.Q. Zeng, E.V. Glass, J. Vahlé, R. Brommage, C.P. Jerome, C.H. Turner, Teriparatide [PTH (1–34)] strengthens the proximal femurs of ovariectomized rats despite increasing porosity, J. Bone Miner. Res. 19 (2004) 623–629.

[226] M. Ellegaard, N.R. Jorgensen, P. Schwarz, Parathyroid hormone and bone healing, Calcif. Tissue Int. 87 (2010) 1–13.

[227] P. Aspenberg, H.K. Genant, T. Johannson, A.J. Nino, K. See, K. Krohn, P.A. Garcia-Hernandez, C.P. Recknor, T.A. Einhorn, G.P. Dalsky, B.H. Miltak, A. Fierlinger, M.C. Laksmanian, Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures, J. Bone Miner. Res. 20 (2005) 404–414.

[228] P. Aspenberg, T. Johannson, Teriparatide improves early callus formation in distal radial fractures: analysis of a subgroup of patients within a randomised, double-blind, three-drug co-allotrialed trial, Acta Orthop. Scand. 83 (2002) 487–494.

[229] P. Peichl, L.A. Holzer, R. Maier, G. Holzer, Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women, J. Bone Jt. Surg. 93 (2011) 1583–1593.

[230] P. Aspenberg, J. Malouf-Sierra, U. Tarantino, P.A. Garcia-Hernandez, C. Corradi, S. Overgaard, J.J. Stepan, L. Borris, E. Lespessailles, F. Frihagen, Effects of Teriparatide compared with risedronate on recovery after pertrochanteric hip fracture, J. Bone Jt. Surg. Am. 98 (2016) 1868–1878.

[231] J. Malouf-Sierra, U. Tarantino, P.A. Garcia-Hernandez, C. Corradi, S. Overgaard, J.J. Stepan, L. Borris, E. Lespessailles, F. Frihagen, Effects of Teriparatide compared with risedronate on recovery after pertrochanteric hip fracture: final results of a 78-week randomized clinical trial, J. Bone Miner. Res. 32 (5) (2017) 1040–1051.

[232] A. Nauth, B. Risteviski, R. Li, E.H. Schemitz, Growth factors and bone regenerative properties of PPR: what can we expect in the future? J. Bone Miner. Res. 21 (2006) 574–581.

[233] R.E. Marx, Platelet-rich plasma (PRP): what is PRP and what is PRP? Implant Dent. 10 (2001) 225–228.

[234] S. Sampson, M. Gerhardt, B. Mandelbaum, Platelet-rich plasma injection grafts for musculoskeletal injuries: a review, Curr. Rev. Musculoskelet. Med. 1 (2008) 165–174.

[235] D. Mandeep, P. Sandeep, B. Kamal, Platelet-rich plasma intra-articular needle injections for the treatment of degenerative cartilage lesions and osteoarthritis in human patellofemoral joint, Knee Surg. Sports Traumatol. Arthrosc. 20 (2012) 1086–1091.

[236] A. Mishra, T. Pavelko, Treatment of chronic elbow tendinosis with buffered platelet-rich plasma, W. Wang, K.W.K. Yeung / Bioactive Materials 2 (2017) 224–247.
bone non-unions, Injury 39 (2008) 1391–1402.

[259] J. Goos, T. Walinski, P. Piekarczyk, K. Kwiatkowski, Results of the use of platelet-rich plasma in the treatment of delayed union of long bones, Ortop. Traumatol. Rehabil. 16 (2013) 397–406.

[260] R. Malhotra, V. Kumar, B. Garg, R. Singh, V. Jain, P. Coshic, K. Chatterjee, Role of autologous platelet-rich plasma in treatment of long-bone nonunions: a prospective study, J. Ultrasound Med. 32 (2013) 211–217.

[261] A. Oryan, S. Alidadi, A. Moshiri, Platelet-rich plasma for bone healing and regeneration, Expert Opin. Biol. Ther. 16 (2016) 213–232.

[262] A. Ruffi, B. Di Matteo, G.S. Krishnakumar, E. Kon, G. Filardo, Platelet-rich plasma for the treatment of bone defects: from preclinical rational to evidence in the clinical practice. A systematic review, Int. Orthop. 41 (2016) 221–237.

[263] D.M. Ranly, M.M. Jacquey, K. Todd, C.H. Lohmann, M. Timothy, A. Rof, B. Han, J. Woodell-May, M. Ponticiello, Z. Yang, M. Nimni, The effect of metal ions on bone tissue engineering, Tissue Eng. Part A 22 (2016) 730–741.

[264] J. Vormann, Magnesium: nutrition and metabolism, Mol. Asp. Med. 24 (2003) 996–1007.

[265] H.G. Classen, S. Baier, H.F. Schimatschek, C.U. Classen, Clinically relevant interactions between hormones and magnesium metabolism – a review, Magnesium: Perspectives in Clinical Research (2007) 1–39.

[266] R.P.H. Thompson, J.J. Powell, G.N. Hampson, Orthosilicic acid stimulates proliferation and differentiation of rat bone marrow mesenchymal stem cell lines, Connect. Tissue Res. 55 (Suppl 1) (2014) 155–162.

[267] E. Quinlan, S. Partap, M.M. Bellucci, R.M. Pereira, S.R. Orrico, Effect of dietary magnesium deficiency on systemic bone density and removal torque of osseointegrated implants, Int. J. Oral Maxillofac. Surg. 25 (2010) 1125–1130.

[268] S. Bernick, G.F. Hungerford, Effect of dietary magnesium deficiency on bones and teeth of rats, J. Dent. Res. 44 (1965) 1317–1324.

[269] G. Stendig-Lindberg, W. Koeller, A. Baur, F.M. Rob, Experimentally induced prolonged magnesium deficiency causes osteoporosis in the rat, Cell. Mol. Life. Lett. 15 (2004) 97–107.

[270] J. Velazquez, A. Jimenez, B. Chomon, T. Villa, Magnesium supplementation of a bone turnover, Nutr. Rev. 57 (1999) 225–229.

[271] H. Zhou, C. Burger, X. Hu, S. Hsiao, B. Gough, N. Graham, M.J. Glomser, Small-angle X-ray study of the three-dimensional collagen/mineral superstructure in intramuscular fish bone, J. Appl. Crystallogr. (2007) 666–668.

[272] C. Serre, M. Papillard, P. Chavasseux, J. Voegel, G. Boivin, Influence of magnesium substitution on a collagen–apatite biomaterial on the production of a calcifying matrix by human osteoblasts, J. Biomed. Mater. Res. 42 (1998) 626–633.

[273] W.R. Schaken, K. Byappara, P. Shuk, R.E. Riman, K.S. TenHuisen, Preparation of magnesium-substituted hydroxypatite powders by the mechanochemical–hydrothermal method, Biomaterials 25 (2004) 4647–4657.

[274] W. Xue, K. Dalhquist, A. Banerjee, A. Bandypadhyay, S. Bose, Synthesis and characterization of tricalcium phosphate with Zn and Mg based dopants, J. Mater. Sci. Mater. Med. 19 (2008) 2669–2677.

[275] E. Landi, G. Logroscino, L. Proietti, A. Tampieri, M. Sandri, S. Sprio, Biomimetic Mg-substituted hydroxypatite: from synthesis to in vivo behaviour, J. Mater. Sci. Mater. Med. 19 (2008) 239–247.

[276] Z. Zhai, X. Xu, H. Li, K. Yang, P. Wán, L. Tan, Z. Ouyang, X. Liu, B. Tian, F. Xiao, W. Wang, C. Jiang, T. Tang, Q. Fan, A. Qin, K. Dai, The effect of metallic magnesium degradation products on osteoclast-induced osteolysis and attenuation of NF-κBp65 and NFATc1 signaling, Biomaterials 35 (2014) 6299–6310.

[277] Y. Zhang, J. Xu, Y.C. Ruan, M.K. Yu, M. O’Laughlin, H. Wise, D. Chen, L. Tian, T. Dai, J. Wang, S. Zvi, B.D. Boyan, Characterization of tricalcium phosphate with Zn and Mg based dopants, J. Biomed. Mater. Res. 88 (2009) 157–166.

[278] L.S. Kwun, R.A. Cho YELomeda, H.L. Jin, Y.H. Choi, Y.H. Kang, J.H. Beattie, Zn2+ deficiency suppresses matrix mineralization and retards osteogenesis transiently with catch-up possibly through Runx 2 modulation, Bone 46 (2010) 726–734.

[279] W. Wang, T.L. Li, H.M. Wong, P.K. Chu, R.Y. Kao, S. Wu, F.K. Leung, T.M. Wong, M.K. To, K.M. Cheung, K.W. Yeung, Development of novel implants with self-antibacterial performance through in-situ growth of 1D ZnO nanowire, Colloids Surf. B Biointerfaces 141 (2016) 623–633.
I. Wilting, F.D. Vries, B.M.K.S. Thio, C. Cooper, E.R. Heerdink, H.G.M. Leufkens, W.A. Nolen, A.C.G. Egberts, T.P.V. Staa, Lithium use and the risk of fractures, Bone 40 (2007) 1252–1258.

C.M. Hedgepeth, L.J. Conrad, J. Zhang, H.C. Huang, V.M. Lee, P.S. Klein, Activation of the Wnt signaling pathway: a molecular mechanism for lithium action, Dev. Biol. 185 (1997) 82–91.

E. Chalecka-Franaszek, D.M. Chuang, Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons, Proc. Natl. Acad. Sci. 96 (1999) 8745–8750.

W. Wei, Z. Lingzhou, W. Kaimin, M. Qianli, M. Shenglin, C. Paul, W. Qintao, Z. Yumei, The role of integrin-linked kinase/β-catenin pathway in the enhanced MG63 differentiation by micro/nano-textured topography, Biomaterials 34 (2013) 631–640.

P. Emilie, L. Héléne, V. Samuel, D. Pascal, L. Myriam, P. Edwige, N. Olivier, B. Myriam, Synergistic effects of CoCl(2) and ROCK inhibition on mesenchymal stem cell differentiation into neuron-like cells, J. Cell. Sci. 8 (2006) 2667–2678.